Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity

This study has been completed.

Study NCT00001577. Last updated on March 3, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00001577

Locations


United States, Maryland
	National Cancer Institute (NCI)
	Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Cancer Institute (NCI)